New York, USA, July 18, 2022 (GLOBE NEWSWIRE) -- Plaque Psoriasis Pipeline Analysis of 75+ Companies | DelveInsight
Plaque psoriasis pipeline constitutes 75+ key companies continuously working towards developing 75+ plaque psoriasis treatment therapies, analyzes DelveInsight. Given the dominance of biologics in the last decade, the current plaque psoriasis pipeline is surprisingly innovative, both in terms of new mechanisms of action as well as new companies entering the development space.
DelveInsight’s 'Plaque Psoriasis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline plaque psoriasis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the plaque psoriasis pipeline domain.
Key Takeaways from the Plaque Psoriasis Pipeline Report
- DelveInsight’s plaque psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for plaque psoriasis treatment.
- Leading plaque psoriasis companies such as Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others are evaluating novel plaque psoriasis treatment drugs candidate to improve the treatment landscape.
- Key plaque psoriasis pipeline therapies in various stages of development includes ARQ-151, ABY-035, AK101, DMB-3115, DLX105-DMP, Deucravacitinib, BAT2306, JNJ-77242113, ME3183, ADX-629, ABP 654, GLPG3667, FYB202, CF101, TLL018, NDI-034858, SCD-044, SHR-1314, Bmab1200, PF-07038124, ONO-4685, CT303, Jaktinib, AUR101, CT-P43, Hemay005, IBI112, SCT630, AT193, and others.
- In May 2022, Bristol Myers Squibb announced two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through up to two years of deucravacitinib treatment, with response rates at Week 60 in the LTE of 77.7% and 58.7% for Psoriasis Area and Severity Index (PASI) 75 and static Physicians Global Assessment (sPGA) 0/1 (clear/almost clear skin), respectively.
- In April 2022, Amgen announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA.
- In March 2022, Arcutis Biotherapeutics announced new pooled results from the DERMIS Phase III trials of roflumilast cream are available in four abstracts at the 2022 American Academy of Dermatology annual meeting, that took place in Boston, MA. Roflumilast is a selective and highly potent phosphodiesterase-4 inhibitor (PDE4) being investigated by Arcutis as a non-steroidal topical treatment for multiple inflammatory skin diseases, including plaque psoriasis.
- In March 2022, Can-Fite BioPharma Ltd. announced that top line data from its Phase III Comfort™ study of Piclidenoson in the treatment of moderate-to-severe plaque psoriasis are scheduled to be released in Q2 2022 due to an unanticipated delay in the collection of study data. The study enrolled more than 400 patients across 30 sites in Europe, Israel, and Canada.
- In May 2022, Nimbus Therapeutics announced the presentation of new data from multiple Phase 1 clinical studies of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in both healthy volunteers and patients with moderate-to-severe psoriasis.Phase 2b clinical studies to evaluate NDI-034858 in moderate-to-severe plaque psoriasis (NCT04999839) and active psoriatic arthritis (NCT05153148) are ongoing.
- In December 2021, Arcutis Biotherapeutics, Inc. announced the U.S. Food and Drug Administration’s (FDA) acceptance for review of the company’s new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022.
- In May 2021, Meiji Seika Pharma Co., Ltd. announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, had been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of a phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings.
Request a sample and discover the recent advances in plaque psoriasis treatment @ Plaque Psoriasis Pipeline Outlook
The plaque psoriasis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage plaque psoriasis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the plaque psoriasis pipeline landscape.
Plaque Psoriasis Overview
Psoriasis is the most common immune-mediated inflammatory disease, affecting the skin and joints and being linked with abnormalities in other systems. The most common type of psoriasis, plaque psoriasis, causes dry, itchy, raised skin patches (plaques) coated in scales. There might be a few or many. They are most commonly found on the elbows, knees, lower back, and scalp. The hue of the patches varies based on the skin tone.
The most common plaque psoriasis symptoms are itchiness, skin pain, joint pain, cracked, dry skin, and others. As psoriasis can resemble eczema and other skin conditions, the plaque psoriasis diagnosis can be difficult. The doctor may need to do a biopsy in some circumstances. The current plaque psoriasis treatment options include topical corticosteroids, phototherapy, vitamin D3 analogs, and retinoids.
Find out more about plaque psoriasis treatment @ Plaque Psoriasis Medications
A snapshot of the Plaque Psoriasis Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| ARQ-151 | Arcutis Biotherapeutics | Preregistration | Type 4 cyclic nucleotide phosphodiesterase inhibitor | Topical |
| SHR 1314 | Jiangsu Hengrui Medicine | Phase III | IL17A protein inhibitor | Subcutaneous |
| AK101 | Akeso Biopharma | Phase III | Interleukin 12 inhibitors; Interleukin 23 inhibitors | Subcutaneous |
| DMB-3115 | Dong-A ST Co., Ltd. | Phase III | Interleukin 12 and 23 inhibitor | Subcutaneous |
| Jaktinib | Suzhou Zelgen Biopharmaceuticals | Phase II | Janus kinase 1,2,3 inhibitors | Oral |
| SCD-044 | Sun Pharmaceutical Industries Limited | Phase II | Sphingosine 1 phosphate receptor agonist | Oral |
| NDI 034858 | Nimbus Therapeutics | Phase II | TYK2 kinase inhibitor | Oral |
| ME3183 | Meiji Pharma | Phase II | Type 4 cyclic nucleotide phosphodiesterase inhibitor | Oral |
| ABY-035 | Affibody | Phase II | IL17A protein inhibitor | Subcutaneous |
| CT 303 | GC Cell Corporation | Phase I | Cell replacement | Intravenous |
Learn more about the novel and emerging plaque psoriasis pipeline therapies @ Plaque Psoriasis Clinical Trials
Plaque Psoriasis Therapeutics Assessment
The plaque psoriasis pipeline report proffers an integral view of the plaque psoriasis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Plaque Psoriasis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Inhalation, Oral, Intranasal, Parenteral, Subcutaneous
- Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
- Therapeutics Assessment By Mechanism of Action: IL17A protein inhibitors, Interleukin 23 inhibitors, Janus kinase 1,2,3 inhibitors, Sphingosine 1 phosphate receptor agonists, Cell replacements, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Interleukin 23 inhibitors
- Key Plaque Psoriasis Companies: Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others
- Key Plaque Psoriasis Pipeline Therapies: ARQ-151, ABY-035, AK101, DMB-3115, DLX105-DMP, Deucravacitinib, BAT2306, JNJ-77242113, ME3183, ADX-629, ABP 654, GLPG3667, FYB202, CF101, TLL018, NDI-034858, SCD-044, SHR-1314, Bmab1200, PF-07038124, ONO-4685, CT303, Jaktinib, AUR101, CT-P43, Hemay005, IBI112, SCT630, AT193, and others.
Dive deep into rich insights for drugs for plaque psoriasis, visit @ Plaque Psoriasis Treatment Drugs
Table of Contents
| 1. | Plaque Psoriasis Pipeline Report Introduction |
| 2. | Plaque Psoriasis Pipeline Report Executive Summary |
| 3. | Plaque Psoriasis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Plaque Psoriasis Pipeline Therapeutics |
| 6. | Plaque Psoriasis Pipeline: Late Stage Products (Pre-registration) |
| 6.1 | ARQ-151: Arcutis Biotherapeutics |
| 7. | Plaque Psoriasis Pipeline: Late Stage Products (Phase III) |
| 7.1 | AK101: Akeso Biopharma |
| 8. | Plaque Psoriasis Pipeline: Mid Stage Products (Phase II) |
| 8.1 | NDI 034858: Nimbus Therapeutics |
| 9. | Plaque Psoriasis Pipeline: Early Stage Products (Phase I) |
| 9.1 | CT 303: GC Cell Corporation |
| 10. | Plaque Psoriasis Pipeline Therapeutic Assessment |
| 11. | Inactive Products in the Plaque Psoriasis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Plaque Psoriasis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the plaque psoriasis pipeline therapeutics, reach out @ Plaque Psoriasis Drugs
Related Reports
Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key plaque psoriasis companies including Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Plaque Psoriasis Epidemiology Forecast
Plaque Psoriasis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted plaque psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Moderate to Severe Plaque Psoriasis Market
Moderate to Severe Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate to severe plaque psoriasis companies including Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Moderate to Severe Plaque Psoriasis Epidemiology Forecast
Moderate to Severe Plaque Psoriasis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted moderate to severe plaque psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Plaque Psoriasis Pipeline
Chronic Plaque Psoriasis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic plaque psoriasis companies, including Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, among others.
Mild to Moderate Plaque Psoriasis Market
Mild to Moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mild to moderate plaque psoriasis companies including Suzhou Zelgen Biopharmaceuticals, Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, BMS, among others.
Other Trending Reports
Periodontal Disease Market | Open-Angle Glaucoma Market | Obsessive-Compulsive Disorder Market | Nicotine Addiction Market | Nephrosclerosis Market | Muscle Invasive Bladder cancer Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market
Related Healthcare Blogs
Upcoming Drugs for Autoimmune Diseases
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
